Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Earnshaw SR, Graham CN, Irish WD, Sato R, Schnitzler MA. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation. J Am Soc Nephrol. 2008 Sep 1;19(9):1807-16.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AR. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul 1;11(4):563-74.
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 Oct 1;23(10):2517-29.
Earnshaw SR, Graham CN, Amonkar MM, Barr CE. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Value Health. 2006 May 1;9(3):A163.